Benjamin D. Moncarz Chief Financial Officer - FDA | Official Website
Benjamin D. Moncarz Chief Financial Officer - FDA | Official Website
This is a 500% increase over the number of companies cited in the previous month.
The citations in the county include:
- Written procedures have not been developed for the surveillance, receipt and evaluation of post marketing adverse drug experiences.
- Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
- Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not include the conclusions and follow-up.
All of the companies cited were involved in either Drugs, Biologics, or Devices sectors.
All of the companies cited should take voluntary actions to correct their managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Advocate Lutheran General Hospital Transfusion Services | Biologics | 12/05/2024 | Procedures to maintain records of emergency transfusions |
Bajaj Medical, LLC | Drugs | 12/04/2024 | Failure to develop written procedures |
Jeron Electronic Systems, Inc. | Devices | 12/04/2024 | Documentation |
Loyola University Medical Center | Biologics | 12/05/2024 | Maintenance - concurrence |
Loyola University Medical Center | Biologics | 12/05/2024 | Establish, maintain and follow manufacturing SOPs |
Sterigenics International, LLC | Devices | 12/17/2024 | Lack of or inadequate procedures |
Vee Pak, LLC | Drugs | 12/10/2024 | Scientifically sound laboratory controls |
Vee Pak, LLC | Drugs | 12/10/2024 | Written record of investigation incomplete |